GEn1E Lifesciences
AI-driven platform developing rapid, novel therapies for rare and inflammatory diseases.
AI-driven platform developing rapid, novel therapies for rare and inflammatory diseases.
GEn1E Lifesciences, founded with the mission to accelerate the development of therapies for rare and inflammatory diseases, leverages an advanced AI platform to create novel immunomodulatory treatments. The company focuses on addressing diseases with no effective treatments by applying AI to multiple-mechanism-of-action protein targets. Their core product offerings include precision therapies developed at an unprecedented pace, with a notable focus on conditions such as Acute Respiratory Distress Syndrome (ARDS).
Key figures affiliated with GEn1E Lifesciences include experts in AI and drug development, though specific names are not provided. The company's AI platform, GRID™, has been instrumental in discovering new binding pockets and validating unique mechanisms of action, contributing to significant advancements in the field. GEn1E's impact is marked by its potential to unlock billion-dollar opportunities in the pharmaceutical industry, positioning it as a transformative player in the development of first-in-class therapies for complex diseases.
Companies similar to GEn1E Lifesciences include Ordaos, Synkrino Biotherapeutics, Arpeggio Biosciences and Genesis Therapeutics.
GEn1E Lifesciences was founded in 2018.
GEn1E Lifesciences' headquarters is located in Palo Alto, CA, US.
GEn1E Lifesciences' most recent funding round was for $17M (USD) in December 2022.
As of Dec 21, 2022, GEn1E Lifesciences has disclosed funding of $17.2M (USD). Undisclosed round amounts are excluded.
GEn1E Lifesciences has 16 employees as of Feb 5, 2024.
Genesis Therapeutics
